Publications
July 14, 2021
International Journal of Toxicology
Preclinical Safety Assessment and Toxicokinetics of Apitegromab, an Antibody Targeting Proforms of Myostatin for the Treatment of Muscle-Atrophying Disease
May 11, 2021
Advances in Therapy
A Randomized Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of the Novel Myostatin Inhibitor Apitegromab (SRK-015): A Potential Treatment for Spinal Muscular Atrophy
March 22, 2021
International Journal of Toxicology
Nonclinical Development of SRK-181: An Anti-Latent TGFβ1 Monoclonal Antibody for the Treatment of Locally Advanced or Metastatic Solid Tumors
Posters
April 2022
2022 European Paediatric Neurology Society Congress (EPNS)
Apitegromab in Spinal Muscular Atrophy (SMA): An Analysis of Multiple Efficacy Endpoints in the TOPAZ Trial (Presentation)
April 2022
American Academy of Neurology (AAN) 2022 Annual Meeting
Apitegromab in Spinal Muscular Atrophy (SMA): An Analysis of Multiple Efficacy Endpoints in the TOPAZ Trial (P15.005)
March 2022
2022 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Apitegromab in SMA: An Analysis of PK/PD Relationships to Efficacy in Ambulatory Patients from the TOPAZ Trial (#72)